SRR934847
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 37.155059132720105
- age_years
- 48
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.444
- G2M_CHECKPOINT+0.426
- TGF_BETA_SIGNALING+0.424
- E2F_TARGETS+0.388
- MYC_TARGETS_V1+0.375
- WNT_BETA_CATENIN_SIGNALING+0.371
- MITOTIC_SPINDLE+0.368
- MYC_TARGETS_V2+0.354
- PROTEIN_SECRETION+0.220
- UNFOLDED_PROTEIN_RESPONSE+0.218
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.462
- MYOGENESIS-0.368
- PANCREAS_BETA_CELLS-0.354
- KRAS_SIGNALING_DN-0.344
- SPERMATOGENESIS-0.303
- OXIDATIVE_PHOSPHORYLATION-0.300
- COAGULATION-0.279
- INFLAMMATORY_RESPONSE-0.265
- FATTY_ACID_METABOLISM-0.258
- XENOBIOTIC_METABOLISM-0.254
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4FC69960-8EF2-49FE-A718-7004E99E00A8 | — | — | 0.928 |
| 2 | SRR934853 | — | — | 0.925 |
| 3 | SRR934880 | — | — | 0.920 |
| 4 | 4A2E75AE-A92F-4497-9253-64AC42CFA745 | — | — | 0.916 |
| 5 | 4549956C-8D25-4B37-894C-E82D5C7684F0 | — | — | 0.913 |
| 6 | SRR934805 | — | — | 0.911 |
| 7 | SRR934823 | — | — | 0.897 |
| 8 | A130FABA-F55F-412D-940E-7305057B4D1A | — | — | 0.892 |
| 9 | A1E55AC6-A41F-454A-A3B6-8F49D2AAFEF2 | — | — | 0.891 |
| 10 | SRR934933 | — | — | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.444 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.426 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.424 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.388 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.375 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.371 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.368 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.354 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.218 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.166 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.155 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.138 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.036 | Temsirolimus | — uncovered |